Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19
Public ClinicalTrials.gov record NCT04655586. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19 (ASPEN-COVID-19)
Study identification
- NCT ID
- NCT04655586
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- ARCA Biopharma, Inc.
- Industry
- Enrollment
- 160 participants
Conditions and interventions
Conditions
Interventions
- rNAPc2 Drug
- Heparin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 9, 2020
- Primary completion
- Dec 5, 2021
- Completion
- Mar 6, 2022
- Last update posted
- Feb 20, 2023
2020 – 2022
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ARCA Investigational Site #119 | Fairhope | Alabama | 36532 | — |
| ARCA Investigational Site #118 | Phoenix | Arizona | 85006 | — |
| ARCA Investigational Site #120 | Tucson | Arizona | 85724 | — |
| ARCA Investigational Site #104 | Aurora | Colorado | 80045 | — |
| ARCA Investigational Site #117 | Denver | Colorado | 80204 | — |
| ARCA Investigational Site #101 | Jacksonville | Florida | 32209 | — |
| ARCA Investigational Site #128 | Evanston | Illinois | 60201 | — |
| ARCA Investigational Site #113 | New Orleans | Louisiana | 70121 | — |
| ARCA Investigational Site #105 | Falls Church | Virginia | 22042 | — |
| ARCA Investigational Site #114 | Richmond | Virginia | 23230 | — |
| ARCA Investigational Site #103 | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04655586, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 20, 2023 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04655586 live on ClinicalTrials.gov.